China Medicine Corporation signed a deal that raises $69.6 million in new capital from One Equity Partners, the private equity investment subsidiary of JPMorgan Chase & Co. It is the first investment for One Equity Partners in China. China Medicine will use the first portion of the money to complete its $21.5 million acquisition of Guangzhou LifeTech Pharma, a transaction that helps move China Medicine from a distribution company into an integrated company with its own drugs to sell. More details...

Stock Symbol: (OTCBB: CHME)